Additionally, we observed that EZH2 inhibition suppressed inflammatory signaling, consistent with prior work suggesting that inflammatory reprogramming is required for lineage transition from prostate adenocarcinoma to NEPC (5). This evidence concerns the gene EZH2 and prostate adenocarcinoma.